Denosumab appears to have a neutral effect on the risk of composite and specific cardiovascular outcomes among patients with primary osteoporosis, whereas romosozumab may contribute to an increased risk of four-point major adverse cardiovascular event, according to the results of a meta-analysis.
The initiation of immune checkpoint inhibitors for cancer in patients with pre-existing autoimmune disease appears to frequently lead to flares or immune-related adverse effects that are mostly manageable, as shown in a study.
Women with rheumatoid arthritis (RA) appear to have low utilization of medications safe to take during pregnancy, commonly discontinuing their medications in the first trimester, a recent study has found.
Among older patients with chronic low back pain and depression who are treated with venlafaxine, exposure to opioids is associated with reduced likelihood of achieving early pain response but not that of attaining the combined pain/depression outcome, a study has shown.
Treatment with pamidronate appears to improve clinical and radiological disease activity in children categorized with extended chronic nonbacterial osteomyelitis (CNO), particularly after 1 year of treatment, a study has shown. However, some children present with active disease after 2 years of pamidronate use.
The oral, selective Janus kinase 1 inhibitor filgotinib confers a significant improvement in health-related quality of life in patients with active psoriatic arthritis (PsA), according to data from the phase II EQUATOR trial.
The CA125* test could be useful at detecting ovarian cancer and various other cancers in the primary care setting, particularly for women aged >50 years, according to a study presented at the recent NCRI** Cancer Conference held in Glasgow, Scotland, UK.
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.